[1] Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell, 2018,175:313-326.
[2] De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J hepatol, 2018,68:1181-1190.
[3] Reddy HG, Schneider BJ, Tai AW. Immune checkpoint inhibitor-associated colits and hepatitis. Clin Transl Gastroenterol, 2018,9:180.
[4] LoPiccolo J, Brener MI, Oshima K, et al. Nodular regenerative hyperplasia associated with immune checkpoint blockade. Hepatology, 2018,68:2431-2433.
[5] Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: A report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology, 1990,11:787-797.
[6] Vuppalanchi R, Mathur K, Pyko M, et al. Liver stiffness measurements in patients with noncirrhotic portal hypertension-the devil is in the details. Hepatology, 2018,68:2438-2440.
[7] Dhanasekaran R, Kwo PY. The liver in oncology. Clin Liver Dis, 2017,21:697-707. |
